South African HIV Investment Case

Research Themes: Costs, Cost-Effectiveness and Benefits of HIV Care and Treatment

Since 2016, annual updates of the HIV Investment Case set out to determine the optimal package of HIV interventions in South Africa, with the aim improve allocative efficiency of HIV funding from the three main sources- the South African government, PEPFAR and the Global Fund. The 2021 HIV Investment Case had the following central additions: For the 95% retention scenario in, we included a hypothetical ART retention intervention that aimed at reaching the UNAIDS target of 95% ART coverage. We also added an optimised package of HIV self-test distribution models, based on our previous work on the cost-effectiveness of HIV self-testing.

Funded by


HE2RO staff involved

Professor Gesine Meyer-Rath Dr. Lise Jamieson Professor Jacqui Miot

Stay up to date

Receive newsletters and keep up to date with developments at HE2RO.